Loading…
Rheuminations
I’ll be honest…it has been 35+ years since I started Medical School [MBBS]. And in the realm of Medicine at large, and Immunology/Rheumatology in specific, we are still struggling to find a ‘cure’ for chronic systemic inflammatory immune-mediated diseases also known as ‘autoimmune rheumatic diseases...
Saved in:
Published in: | J. Islamic Int. Med. Coll. 2022-12, Vol.17 (4), p.236-238 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 238 |
container_issue | 4 |
container_start_page | 236 |
container_title | J. Islamic Int. Med. Coll. |
container_volume | 17 |
creator | Kaushik, Dr. Prashant Kaushik, Aarya A. |
description | I’ll be honest…it has been 35+ years since I started Medical School [MBBS]. And in the realm of Medicine at large, and Immunology/Rheumatology in specific, we are still struggling to find a ‘cure’ for chronic systemic inflammatory immune-mediated diseases also known as ‘autoimmune rheumatic diseases (ARD)’. Rheumatology is still in its cradle having gotten the recognition as a subspecialty of Medicine only in 1972. I have seen the field evolve in terms of understanding the orchestrated ‘play’ of the immune cells along with cytokines etc. over the past 3 decades, all of which has led to the concept and birth of ‘biologic’ disease modifying anti-rheumatic drugs [b-DMARDs]. The first b-DMARD to get approved by the Food and Drugs Administration [FDA] was etanercept, a TNF-alpha receptor fusion protein in 1998. Infliximab, a chimeric monoclonal antibody against TNF soon followed in 1999. Ever since then, there has been a flurry of b-DMARDs including 3 more in the same family of TNF-antagonists, 2 in the Interleukin [IL]-6 antagonist class, 1 blocker of the second co-stimulatory T-cell signaling: CTLA-4Ig, 3 IL-1 antagonists, B-cell depleting chimeric monoclonal antibody directed against CD-20 etc. Also, 3 oral Janus-kinase inhibitors have joined the ‘gang’ and are called targeted synthetic DMARDs. I still remember the pre-b-DMARD era when rip roaring rheumatoid arthritis was still around, and with my Ustaad Saheb (Mentor), all what we had to offer pharmaceutically were the conventional synthetic [cs] DMARDs including methotrexate, hydroxychloroquine, sulfasalazine, leflunomide and [the younger generation can hold their breath] cyclosporine, d-penicillamine, chlorambucil…GOLD injections and even cyclophosphamide! Corticosteroids have been around since 1950! The 1st and “so far” […well, I/You might be next one!] the only Nobel Prize winning revelation in the realm of Rheumatology... |
doi_str_mv | 10.57234/1621 |
format | article |
fullrecord | <record><control><sourceid>doaj_cross</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_91429d0cf4ee4abf85c38b1b37a3141c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_91429d0cf4ee4abf85c38b1b37a3141c</doaj_id><sourcerecordid>oai_doaj_org_article_91429d0cf4ee4abf85c38b1b37a3141c</sourcerecordid><originalsourceid>FETCH-LOGICAL-c166t-a9720867cfdf1fd2ef7a42f6d8f095d0c26cd57d4913486dc88336c4e309aadc3</originalsourceid><addsrcrecordid>eNo90MtKA0EQheFGFBziPIbL0arumr4sJXgJBATRdVPTF52QZKR7XPj2mkRcHTiLb_EL0SLc9EYqukUt8Uw0khC6nqQ8Fw1a7DsCtJeirXUDANIhGpCNaF8-0tdu3PM8Tvt6JS4yb2tq_3Yh3h7uX5dP3fr5cbW8W3cBtZ47dkaC1SbkmDFHmbJhkllHm8H1EYLUIfYmkkNFVsdgrVI6UFLgmGNQC7E6uXHijf8s447Lt5949MdjKu-eyzyGbfIOSbpfMlNKxEO2fVB2wEEZVkh4sK5PVihTrSXlfw_BH5P4QxL1A9gvUDA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Rheuminations</title><source>Alma/SFX Local Collection</source><creator>Kaushik, Dr. Prashant ; Kaushik, Aarya A.</creator><creatorcontrib>Kaushik, Dr. Prashant ; Kaushik, Aarya A.</creatorcontrib><description>I’ll be honest…it has been 35+ years since I started Medical School [MBBS]. And in the realm of Medicine at large, and Immunology/Rheumatology in specific, we are still struggling to find a ‘cure’ for chronic systemic inflammatory immune-mediated diseases also known as ‘autoimmune rheumatic diseases (ARD)’. Rheumatology is still in its cradle having gotten the recognition as a subspecialty of Medicine only in 1972. I have seen the field evolve in terms of understanding the orchestrated ‘play’ of the immune cells along with cytokines etc. over the past 3 decades, all of which has led to the concept and birth of ‘biologic’ disease modifying anti-rheumatic drugs [b-DMARDs]. The first b-DMARD to get approved by the Food and Drugs Administration [FDA] was etanercept, a TNF-alpha receptor fusion protein in 1998. Infliximab, a chimeric monoclonal antibody against TNF soon followed in 1999. Ever since then, there has been a flurry of b-DMARDs including 3 more in the same family of TNF-antagonists, 2 in the Interleukin [IL]-6 antagonist class, 1 blocker of the second co-stimulatory T-cell signaling: CTLA-4Ig, 3 IL-1 antagonists, B-cell depleting chimeric monoclonal antibody directed against CD-20 etc. Also, 3 oral Janus-kinase inhibitors have joined the ‘gang’ and are called targeted synthetic DMARDs. I still remember the pre-b-DMARD era when rip roaring rheumatoid arthritis was still around, and with my Ustaad Saheb (Mentor), all what we had to offer pharmaceutically were the conventional synthetic [cs] DMARDs including methotrexate, hydroxychloroquine, sulfasalazine, leflunomide and [the younger generation can hold their breath] cyclosporine, d-penicillamine, chlorambucil…GOLD injections and even cyclophosphamide! Corticosteroids have been around since 1950! The 1st and “so far” […well, I/You might be next one!] the only Nobel Prize winning revelation in the realm of Rheumatology...</description><identifier>ISSN: 1815-4018</identifier><identifier>EISSN: 2410-5422</identifier><identifier>DOI: 10.57234/1621</identifier><language>eng</language><publisher>Riphah International University, Islamabad</publisher><ispartof>J. Islamic Int. Med. Coll., 2022-12, Vol.17 (4), p.236-238</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Kaushik, Dr. Prashant</creatorcontrib><creatorcontrib>Kaushik, Aarya A.</creatorcontrib><title>Rheuminations</title><title>J. Islamic Int. Med. Coll.</title><description>I’ll be honest…it has been 35+ years since I started Medical School [MBBS]. And in the realm of Medicine at large, and Immunology/Rheumatology in specific, we are still struggling to find a ‘cure’ for chronic systemic inflammatory immune-mediated diseases also known as ‘autoimmune rheumatic diseases (ARD)’. Rheumatology is still in its cradle having gotten the recognition as a subspecialty of Medicine only in 1972. I have seen the field evolve in terms of understanding the orchestrated ‘play’ of the immune cells along with cytokines etc. over the past 3 decades, all of which has led to the concept and birth of ‘biologic’ disease modifying anti-rheumatic drugs [b-DMARDs]. The first b-DMARD to get approved by the Food and Drugs Administration [FDA] was etanercept, a TNF-alpha receptor fusion protein in 1998. Infliximab, a chimeric monoclonal antibody against TNF soon followed in 1999. Ever since then, there has been a flurry of b-DMARDs including 3 more in the same family of TNF-antagonists, 2 in the Interleukin [IL]-6 antagonist class, 1 blocker of the second co-stimulatory T-cell signaling: CTLA-4Ig, 3 IL-1 antagonists, B-cell depleting chimeric monoclonal antibody directed against CD-20 etc. Also, 3 oral Janus-kinase inhibitors have joined the ‘gang’ and are called targeted synthetic DMARDs. I still remember the pre-b-DMARD era when rip roaring rheumatoid arthritis was still around, and with my Ustaad Saheb (Mentor), all what we had to offer pharmaceutically were the conventional synthetic [cs] DMARDs including methotrexate, hydroxychloroquine, sulfasalazine, leflunomide and [the younger generation can hold their breath] cyclosporine, d-penicillamine, chlorambucil…GOLD injections and even cyclophosphamide! Corticosteroids have been around since 1950! The 1st and “so far” […well, I/You might be next one!] the only Nobel Prize winning revelation in the realm of Rheumatology...</description><issn>1815-4018</issn><issn>2410-5422</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNo90MtKA0EQheFGFBziPIbL0arumr4sJXgJBATRdVPTF52QZKR7XPj2mkRcHTiLb_EL0SLc9EYqukUt8Uw0khC6nqQ8Fw1a7DsCtJeirXUDANIhGpCNaF8-0tdu3PM8Tvt6JS4yb2tq_3Yh3h7uX5dP3fr5cbW8W3cBtZ47dkaC1SbkmDFHmbJhkllHm8H1EYLUIfYmkkNFVsdgrVI6UFLgmGNQC7E6uXHijf8s447Lt5949MdjKu-eyzyGbfIOSbpfMlNKxEO2fVB2wEEZVkh4sK5PVihTrSXlfw_BH5P4QxL1A9gvUDA</recordid><startdate>20221229</startdate><enddate>20221229</enddate><creator>Kaushik, Dr. Prashant</creator><creator>Kaushik, Aarya A.</creator><general>Riphah International University, Islamabad</general><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope></search><sort><creationdate>20221229</creationdate><title>Rheuminations</title><author>Kaushik, Dr. Prashant ; Kaushik, Aarya A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c166t-a9720867cfdf1fd2ef7a42f6d8f095d0c26cd57d4913486dc88336c4e309aadc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaushik, Dr. Prashant</creatorcontrib><creatorcontrib>Kaushik, Aarya A.</creatorcontrib><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>J. Islamic Int. Med. Coll.</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaushik, Dr. Prashant</au><au>Kaushik, Aarya A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rheuminations</atitle><jtitle>J. Islamic Int. Med. Coll.</jtitle><date>2022-12-29</date><risdate>2022</risdate><volume>17</volume><issue>4</issue><spage>236</spage><epage>238</epage><pages>236-238</pages><issn>1815-4018</issn><eissn>2410-5422</eissn><abstract>I’ll be honest…it has been 35+ years since I started Medical School [MBBS]. And in the realm of Medicine at large, and Immunology/Rheumatology in specific, we are still struggling to find a ‘cure’ for chronic systemic inflammatory immune-mediated diseases also known as ‘autoimmune rheumatic diseases (ARD)’. Rheumatology is still in its cradle having gotten the recognition as a subspecialty of Medicine only in 1972. I have seen the field evolve in terms of understanding the orchestrated ‘play’ of the immune cells along with cytokines etc. over the past 3 decades, all of which has led to the concept and birth of ‘biologic’ disease modifying anti-rheumatic drugs [b-DMARDs]. The first b-DMARD to get approved by the Food and Drugs Administration [FDA] was etanercept, a TNF-alpha receptor fusion protein in 1998. Infliximab, a chimeric monoclonal antibody against TNF soon followed in 1999. Ever since then, there has been a flurry of b-DMARDs including 3 more in the same family of TNF-antagonists, 2 in the Interleukin [IL]-6 antagonist class, 1 blocker of the second co-stimulatory T-cell signaling: CTLA-4Ig, 3 IL-1 antagonists, B-cell depleting chimeric monoclonal antibody directed against CD-20 etc. Also, 3 oral Janus-kinase inhibitors have joined the ‘gang’ and are called targeted synthetic DMARDs. I still remember the pre-b-DMARD era when rip roaring rheumatoid arthritis was still around, and with my Ustaad Saheb (Mentor), all what we had to offer pharmaceutically were the conventional synthetic [cs] DMARDs including methotrexate, hydroxychloroquine, sulfasalazine, leflunomide and [the younger generation can hold their breath] cyclosporine, d-penicillamine, chlorambucil…GOLD injections and even cyclophosphamide! Corticosteroids have been around since 1950! The 1st and “so far” […well, I/You might be next one!] the only Nobel Prize winning revelation in the realm of Rheumatology...</abstract><pub>Riphah International University, Islamabad</pub><doi>10.57234/1621</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1815-4018 |
ispartof | J. Islamic Int. Med. Coll., 2022-12, Vol.17 (4), p.236-238 |
issn | 1815-4018 2410-5422 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_91429d0cf4ee4abf85c38b1b37a3141c |
source | Alma/SFX Local Collection |
title | Rheuminations |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T13%3A05%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rheuminations&rft.jtitle=J.%20Islamic%20Int.%20Med.%20Coll.&rft.au=Kaushik,%20Dr.%20Prashant&rft.date=2022-12-29&rft.volume=17&rft.issue=4&rft.spage=236&rft.epage=238&rft.pages=236-238&rft.issn=1815-4018&rft.eissn=2410-5422&rft_id=info:doi/10.57234/1621&rft_dat=%3Cdoaj_cross%3Eoai_doaj_org_article_91429d0cf4ee4abf85c38b1b37a3141c%3C/doaj_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c166t-a9720867cfdf1fd2ef7a42f6d8f095d0c26cd57d4913486dc88336c4e309aadc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |